by Barry McGuinness | Dec 2, 2024 | Announcement, Precision Oncology
First Patient Dosed in Phase I Trial with DSB2455 Duke Street Bio Ltd, a precision medicine biotech developing next generation small molecule cancer therapies, is pleased to announce that the first patient has been dosed in a Phase I trial evaluating the highly...
by Barry McGuinness | Sep 24, 2024 | Announcement
Next-Generation PARP1-Selective Inhibitor Trial Duke Street Bio Ltd, a precision medicine biotech developing next generation small molecule cancer therapies, is pleased to announce that the European Medicines Agency (EMA) has granted approval to commence a clinical...
by Barry McGuinness | Jun 26, 2023 | Announcement
Duke Street Bio Announces Appointment of Head of Clinical Operations Duke Street Bio, a London based biotech focusing on the discovery of novel precision medicine-based cancer therapies, today strengthens its leadership team with the appointment of Jeff Thompson, PhD,...
by Barry McGuinness | Mar 28, 2023 | Announcement
Duke Street Bio Announces Appointment of Chief Medical Officer Duke Street Bio is delighted to announce the strengthening of its executive leadership team with the appointment of Dónal Landers, MB BCh BAO, MBA, DPM, FFPM as Chief Medical Officer. Dr Landers is a...
by Barry McGuinness | May 22, 2022 | Drug discovery programmes, Immuno-oncology
Duke Street Bio – DDR & IO biotech emerges from stealth mode to discuss its next generation PARP1 and PARP7 inhibitor programmes Since 2019 the management team behind small molecule immuno-oncology biotech IOmet Pharma, acquired by Merck & Co (known as...
Recent Comments